Kristin Abate, Karyopharm Therapeutics Inc.'s chief accounting officer, sold 50 shares of the company's common stock on January 28 at $7.03 per share in a transaction that totaled $351. The sale was disclosed on a Form 4 filed with the Securities and Exchange Commission and was carried out under a pre-arranged automatic sale plan intended to cover withholding tax obligations that arose when performance-based restricted stock units vested.
The filing shows that the sale followed a separate transaction on January 27, when Abate was credited with 92 shares of Karyopharm common stock. Those shares reflect performance-based restricted stock units (PSUs) that were originally granted in February 2023 and that vested on January 27, 2026 after the company’s Compensation Committee certified that revenue and shareholder return targets had been met.
After both transactions, Abate is reported to directly own 22,622 shares of Karyopharm Therapeutics common stock.
At the time of the January 28 sale, Karyopharm carried a market capitalization of $122.31 million. The company’s quoted share price has since declined from the transaction price, trading at $6.63 following the sale.
Analytical coverage from InvestingPro cited in the company filings and disclosures indicates that, despite a 67.55% increase in Karyopharm's share price over the prior six months, the platform views the stock as slightly undervalued. InvestingPro assigns the company a "FAIR" financial health rating and notes that Karyopharm faces cash burn concerns as it approaches its next scheduled earnings report on February 17. InvestingPro also provides more extensive analysis and a dedicated Pro Research Report for users seeking additional detail.
Corporate results cited in recent company reporting show a 13.4% increase in total revenue for the third quarter of 2025, with total revenue reaching $44 million. For the same quarter, Karyopharm recorded a net loss of $33.1 million, equating to earnings per share of -$3.82.
Preliminary, unaudited estimates for full-year 2025 indicate total revenue of approximately $145 million, with U.S. net product revenue for XPOVIO (selinexor) running near $115 million.
Institutional analyst commentary referenced in disclosures underscores continued investor interest: Piper Sandler has reaffirmed an Overweight rating and a $12.00 price target, naming Karyopharm a top pick for 2026 in light of anticipated Phase III trial results; RBC Capital has maintained an Outperform rating and a $19.00 target, highlighting optimism about selinexor’s potential in treating myelofibrosis. The Phase III SENTRY trial results for selinexor are expected in March 2026 and are cited as a catalyst attracting attention from investors and analysts.
The transactions by Abate - a routine tax-related liquidation tied to vesting PSUs - come amid a backdrop of revenue growth, ongoing net losses, analyst optimism, and near-term milestones that market participants are monitoring.